China Oncology ›› 2021, Vol. 31 ›› Issue (1): 1-10.doi: 10.19401/j.cnki.1007-3639.2021.01.001

• Specialists’ Commentary and Article • Previous Articles     Next Articles

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2020

TANG Rong, SHI Si, ZHANG Bo, XU Jin, WANG Wei, YU Xianjun#br#   

  1. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute, Shanghai 200032, China
  • Online:2021-01-30 Published:2021-02-20
  • Contact: YU Xianjun E-mail: yuxianjun@fudanpci.org

Abstract: Pancreatic cancer is one of the more dismal gastrointestinal tumors due to the obscure symptoms in the early stage of disease, rapid progression and insensitivity to chemotherapy. The 5-year survival rate is only approximately 9% for patients with pancreatic cancer. In the recent years, with the change in dietary structure and life style as well as the improvement of clinical detection rate, the incidence of pancreatic cancer is increasing annually, and it severely undermines the health of people. However, the advance in molecular biology provides more potential targets for the treatment of pancreatic cancer. Besides, well-conducted clinical trials continue to translate more theoretical innovations from bench to bedside. These both can improve the prognosis of pancreatic cancer eventually. The present review summarized the important findings in pancreatic cancer research in 2020.

Key words: Pancreatic cancer, Basic research, Clinical research